

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Gerhard SEEMANN et al.

National Phase of PCT/EP98/01438

Serial No.: Not yet assigned

Group Art Unit:

Filed: September 20, 1999

Examiner:

For: EXTENSION OF THE EXPRESSION OF TRANSGENIC PROTEINS BY IMMUNOMODULATION

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicants bring to the Examiner's attention the documents listed on attached Form PTO-1449 and cited in the international search report. Copies of the listed documents are attached. Applicants respectfully request that the Examiner consider the documents listed on attached Form PTO-1449 and indicate that they were considered by making an appropriate notation on this form.

This Information Disclosure Statement is being filed with the above-referenced application.

In lieu of a statement of relevance or the translation of the non-English documents, enclosed is an English-language international search report from the European Patent Office in the PCT international application, from which this national phase U.S. application is derived, citing these documents and setting forth the relevance thereof.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: 
Carol P. Einaudi
Reg. No. 32,220

Dated: September 20, 1999

Enclosures
CPE/FPD/cm

LAW OFFICES

FINNEGAN, HENDERSON,
FARABOW, GARRETT
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

INFORMATION DISCLOSURE CITATION
 (Us several sheets if necessary)

PAGE 2 OF 2

Atty. Docket No. 2481.1640	Serial No. Not Yet Assigned						
Applicant Gerhard SEEMANN et al.							
Filing Date September 20, 1999	Group						
U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub Class	Translation Yes or No
		0 551 230	07/14/93	Europe			No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	W. Solbach et al., "Protective Effect of Leflunomide on the Natural Course of Leishmania Major-Induced Disease in Genetically Susceptible Balb/c Mice", XP-002074077, Int. J. Immunopharmacol., Vol. 17, No. 6, pp. 481-488, (1995).						
	J.R. Kalden et al., "New Therapeutic Approaches in Autoimmune Rheumatic Diseases with Special Emphasis on Rheumatoid Arthritis", XP-002074078, British J. Rheumatol., Vol. 34, No. 3, pp. 193-196, (1995).						
	T. Zielinski et al., "Leflunomide, a reversible inhibitor of pyrimidine biosynthesis?", XP-002061643, Inflamm. Res., Vol. 44, No. 2, pp. S207-S208, (1995).						
	Reynolds: "Martindale - The Extra Pharmacopoeia.", XP-002074427, Royal Pharmaceutical Society, London, pp. 557-562 and 599-600, (1996).						
	G. Burg, "Dermatologie 1997: Immunintervention auf dem Vormarsch", XP-002074079, Schweizerische Medizinische Wochenschrift, Vol. 128, No. 1-2, pp. 18-20, (1998).						
Examiner				Date Considered			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
Form PTO 1449				Patent and Trademark Office - U.S. Department of Commerce			

09/381344

OMB No. 0651-0011

420 Rec'd PCT/PTO 20 SEP 1999

INFORMATION DISCLOSURE CITATION
(Use sev ral sheets if necessary)

PAGE 1 OF 2

Atty. Docket No. 2481.1640				Serial No. Not Yet Assigned			
Applicant Gerhard SEEMANN et al.							
Filing Date September 20, 1999				Group			
U.S. PATENT DOCUMENTS							
Examiner Initial*		Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub Class	Translation Yes or No
		WO 96/40170	12/19/96	WIPO/PCT			
		0 607 775	07/27/94	Europe			No
		0 821 952	02/04/98	Europe			No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
S. Hayashi et al., "Adenovirus-Mediated Gene Transfer to the Xenogeneic Liver in Liver Xenotransplantation: The Transduction of Complement Regulatory Factor Genes (DAF and HRF20)", XP-002074074, Cell Transplantation, Vol. 5, No. 5, Suppl. 2, p. 73 (1996).							
S. Greene et al., "Inhibition of Dihydroorotate Dehydrogenase by the Immunosuppressive Agent Leflunomide", XP-002074075, Biochem. Pharmacol., Vol. 50, No. 6, pp. 861-867, (1995).							
R.R. Bartlett et al., "Leflunomide (HWA 486), a Novel Immunomodulating Compound for the Treatment of Autoimmune Disorders and Reactions Leading to Transplantation Rejection", XP-002074076, Agents and Actions, Vol. 32, No. 1-2, pp. 10-21, (1991).							
Examiner				Date Considered			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
Form PTO 1449				Patent and Trademark Office - U.S. Department of Commerce			